Results 11 to 20 of about 10,553 (193)

Redo pelvic fracture urethral injury repair: The case for tadalafil

Urology Research and Practice, 2021
Objective: To define the role of tadalafil in improving outcomes of redo urethroplasty for pelvic fracture urethral injury (PFUI). PFUI is common in developing countries, invariably as a result of road traffic trauma.
Devashree P. Joshi, Devang Desai, Seichi Fuziwara, Sheliyan Raveenthiran, Mohammed Nafea, Sanjay B. Kulkarni   +5 more
doaj   +2 more sources

Assessing the therapeutic potential of PDE‐5 inhibitors in adults: Insights from a multi‐omics study [PDF]

Physiological Reports, Volume 14, Issue 18, September 2026.
Abstract Phosphodiesterase‐5 inhibitors have beneficial pleiotropic effects and hold promise as adjuvant treatments for cancer, dementia, and other disorders. Sixteen men and women aged 50–60 were administered daily sildenafil/tadalafil for 1 month. We characterized molecular signatures of sildenafil/tadalafil treatment via analyses and multi‐omics ...
Kristen A. McGovern, Traver J. Wright, Erik D. Marchant, Sean P. Kilroe, William J. Durham, E. Lichar Dillon, Marc M. Baum, Michael P. Kinsky, William K. Russell, Christopher S. Fry, Pratik Gongloor, Richard B. Pyles, Randall J. Urban, Blake B. Rasmussen, Melinda Sheffield‐Moore   +14 more
wiley   +2 more sources

Potential of tadalafil and tadalafil-cellulose nanocomposite in preventing postsurgical abdominal adhesions in a rat cecal abrasion model

Scientific Reports
The formation of postoperative intra-abdominal adhesions is a significant challenge in veterinary practice worldwide. Thus, several attempts have been made to identify agents that prevent the occurrence of these postsurgical adhesions.
Ahmed Abdelrahiem Sadek, Mahmoud S. Sabra, Marwa F. Ali, Hani Nasser Abdelhamid, Kamal Hussein   +4 more
doaj   +2 more sources

Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension

Therapeutic Advances in Respiratory Disease, 2013
The purpose of this review is to evaluate the use of tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension (PAH).
Dioma U. Udeoji, Ernst R. Schwarz
doaj   +2 more sources

Comparative efficacy of on-demand Sildenafil, Tadalafil and daily Tadalafil for treatment of erectile dysfunction: A 12-week randomized controlled study [PDF]

Indian Journal of Psychiatry
Background: Comparison of available first line agents for treating Erectile Dysfunction (ED) with each other regarding efficacy in Indian context remains scant.
Shevya Gagal, Ajeet K. Sidana, Abhinav Agrawal, Swarndeep Singh   +3 more
doaj   +2 more sources

Tadalafil: an overview and the post-mortem toxicology of a case [PDF]

International Journal of Medical Toxicology and Forensic Medicine, 2023
Tadalafil is an inhibitor of the enzyme human cyclic guanosine monophosphate–specific phosphodiesterase, type 5 (PDE-5). A mild vasodilator, it is primarily used for the treatment of erectile dysfunction (ED), an increasingly common condition.
Maria Laura Schirripa, Letizia Gnetti, Edda Emanuela Guareschi   +2 more
doaj   +2 more sources

The Efficacy and Safety of Tamsulosin and Tadalafil Combination Therapy Compared with Tadalafil Alone for Patients with Benign Prostatic Hyperplasia [PDF]

Scripta Score Scientific Medical Journal
Background: Benign prostatic hyperplasia (BPH) is a common urologic condition in aging men that often manifests as lower urinary tract symptoms (LUTS).
Mochammad Haikal Alhamdi, Siti Nurhijrati Hasanah   +1 more
doaj   +3 more sources

Enhanced Bioavailability of Tadalafil after Intranasal Administration in Beagle Dogs

Pharmaceutics, 2018
Tadalafil is an oral selective phosphodiesterase type-5 inhibitor with demonstrated efficacy and safety that is used to treat erectile dysfunction. The purpose of this study is to compare the pharmacokinetic properties of tadalafil after conventional ...
Jeong-Soo Kim, Min-Soo Kim, In-hwan Baek
doaj   +2 more sources

Combination of tadalafil and finasteride for improving the symptoms of benign prostatic hyperplasia: critical appraisal and patient focus [PDF]

Therapeutics and Clinical Risk Management, 2015
Osama O Elkelany, Ryan C Owen, Edward D KimDepartment of Surgery, Division of Urology, University of Tennessee Graduate School of Medicine, Knoxville, TN, USAAbstract: The evidence suggests that combination therapy for benign prostatic hyperplasia (BPH ...
Elkelany OO, Owen RC, Kim ED
doaj   +1 more source

Temporal Trends in Intracavernosal Injection Therapy and Penile Prosthesis Implantation in the Era of Phosphodiesterase‐5 Inhibitors for Erectile Dysfunction in Australia [PDF]

ANZ Journal of Surgery, Volume 96, Issue 9, Page 2498-2505, September 2026.
ABSTRACT Introduction Phosphodiesterase‐5 inhibitors (PDE5‐Is) transformed erectile dysfunction (ED) management as first‐line therapy; nonetheless, many patients require second‐ and third‐line options due to inadequate response, side effects, or contraindications.
Nicholas Gillman, Eric Chung
wiley   +2 more sources